See more : Bros Eastern.,Ltd (601339.SS) Income Statement Analysis – Financial Results
Complete financial analysis of HEXO Corp. (HEXO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of HEXO Corp., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Access Co., Ltd. (4813.T) Income Statement Analysis – Financial Results
- Allied Architects, Inc. (6081.T) Income Statement Analysis – Financial Results
- India Shelter Finance Corporation Limited (INDIASHLTR.BO) Income Statement Analysis – Financial Results
- Jiangsu Rijiu Optoelectronics Jointstock Co., Ltd (003015.SZ) Income Statement Analysis – Financial Results
- Ottakringer Getränke AG (OTS.VI) Income Statement Analysis – Financial Results
HEXO Corp. (HEXO)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.hexocorp.com
About HEXO Corp.
HEXO Corp., through its subsidiaries, produces, markets, and sells cannabis in Canada. The company offers its adult-use and medical products under the HEXO brand name. It also provides cannabis beverages under the Little Victory, House of Terpenes, Mollo, Veryvell, and XMG brands; and cannabis products under UP Cannabis, Original Stash, and Up brand names. HEXO Corp. has a strategic alliance with Tilray Brands, Inc. The company was formerly known as The Hydropothecary Corporation and changed its name to HEXO Corp. in August 2018. HEXO Corp. was founded in 2013 and is headquartered in Gatineau, Canada.
Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
---|---|---|---|---|---|---|---|---|---|
Revenue | 191.10M | 123.77M | 80.78M | 47.54M | 4.93M | 4.10M | 0.00 | 0.00 | 0.00 |
Cost of Revenue | 266.78M | 74.97M | 138.76M | 20.62M | -1.47M | -2.35M | 0.00 | 0.00 | 0.00 |
Gross Profit | -75.67M | 48.80M | -57.98M | 26.93M | 6.40M | 6.45M | 0.00 | 0.00 | 0.00 |
Gross Profit Ratio | -39.60% | 39.43% | -71.77% | 56.64% | 129.72% | 157.39% | 0.00% | 0.00% | 0.00% |
Research & Development | 3.22M | 3.84M | 4.64M | 2.82M | 0.00 | 86.38K | 0.00 | 0.00 | 0.00 |
General & Administrative | 99.31M | 69.92M | 78.58M | 73.96M | 14.37M | 4.27M | 0.00 | 29.29K | 29.29K |
Selling & Marketing | 22.93M | 10.35M | 12.47M | 31.19M | 8.34M | 2.99M | 0.00 | 0.00 | 0.00 |
SG&A | 122.24M | 80.27M | 91.06M | 105.15M | 22.71M | 7.25M | 0.00 | 29.29K | 29.29K |
Other Expenses | 28.78M | 8.15M | 322.88M | 3.51M | 1.66M | 0.00 | 0.00 | 0.00 | 0.00 |
Operating Expenses | 154.24M | 92.25M | 418.58M | 111.48M | 24.37M | 7.93M | 0.00 | 29.29K | 29.29K |
Cost & Expenses | 421.01M | 167.22M | 557.34M | 132.10M | 22.90M | 5.58M | 0.00 | 29.29K | 29.29K |
Interest Income | 1.65M | 1.60M | 1.90M | 5.19M | 2.12M | 92.16K | 0.00 | 0.00 | 0.00 |
Interest Expense | 20.07M | 32.12M | 10.04M | 469.00K | 1.53M | 522.62K | 0.00 | 0.00 | 0.00 |
Depreciation & Amortization | 810.10M | 16.73M | 68.25M | 5.85M | 1.66M | 591.65K | 22.82K | 0.00 | 0.00 |
EBITDA | -257.63M | -26.73M | -476.55M | -78.70M | -14.19M | -1.75M | 0.00 | -29.29K | -29.29K |
EBITDA Ratio | -134.81% | -21.59% | -589.91% | -165.55% | -287.60% | -42.73% | 0.00% | 0.00% | 0.00% |
Operating Income | -1.07B | -43.45M | -476.55M | -84.56M | -17.97M | -1.48M | 0.00 | -29.29K | -29.29K |
Operating Income Ratio | -558.72% | -35.11% | -589.91% | -177.86% | -364.14% | -36.21% | 0.00% | 0.00% | 0.00% |
Total Other Income/Expenses | -691.53M | -71.71M | -75.96M | -847.00K | -5.38M | -10.93M | 0.00 | 0.00 | 0.00 |
Income Before Tax | -1.11B | -115.16M | -552.51M | -85.40M | -23.35M | -12.42M | 0.00 | -29.29K | -29.29K |
Income Before Tax Ratio | -582.11% | -93.04% | -683.94% | -179.64% | -473.25% | -303.10% | 0.00% | 0.00% | 0.00% |
Income Tax Expense | -38.81M | -397.00K | -6.02M | -3.84M | 1.53M | 522.62K | 0.00 | 0.00 | 0.00 |
Net Income | -1.07B | -114.76M | -546.49M | -81.56M | -23.35M | -12.42M | 0.00 | -29.29K | -29.29K |
Net Income Ratio | -561.80% | -92.72% | -676.48% | -171.57% | -473.25% | -303.10% | 0.00% | 0.00% | 0.00% |
EPS | -38.68 | -12.62 | -63.43 | -21.47 | -9.75 | -11.88 | 0.00 | -0.92 | 0.00 |
EPS Diluted | -38.68 | -12.62 | -63.43 | -21.47 | -9.75 | -11.88 | 0.00 | -0.92 | 0.00 |
Weighted Avg Shares Out | 27.76M | 9.09M | 8.62M | 3.80M | 2.40M | 1.05M | 31.54M | 31.75K | 6.22M |
Weighted Avg Shares Out (Dil) | 27.76M | 9.09M | 8.62M | 3.80M | 2.40M | 1.05M | 31.54M | 31.75K | 6.22M |
Hexo Corp.'s Shareholders Approve Acquisition by Way of Arrangement With Tilray Brands, Inc.
HEXO to Host Third Quarter 2023 Earnings Conference Call
Top Canadian Penny Stocks To Buy? 3 To Watch
HEXO Announces Closing of Non-Brokered Private Placement and Amendments to Arrangement Agreement and Waiver and Amendment Agreement
Don't Avoid All Canadian Cannabis Producers
Leading Independent Proxy Advisory Firm ISS Recommends HEXO Shareholders Vote FOR the Arrangement Agreement with Tilray Brands
Top Marijuana Stocks To Invest In 2023
Canadian Cannabis Stocks Under $2 To Watch Now
HEXO Corp. Files Circular for Special Meeting of Shareholders to Approve Arrangement With Tilray Brands, Inc.
HEXO Corp. Files Circular for Special Meeting of Shareholders to Approve Arrangement With Tilray Brands, Inc.
Source: https://incomestatements.info
Category: Stock Reports